1.62 +0.03 (1.89%)
After hours: 5:21PM EDT
|Bid||1.58 x 900|
|Ask||1.62 x 3100|
|Day's Range||1.57 - 1.64|
|52 Week Range||1.09 - 6.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it is set to join the broad-market Russell 3000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on June 25, 2018, according to the final list of additions posted on June 22, 2018. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of May 11, 2018, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
MannKind Corporation (MNKD) announced that additional data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) will be presented in an oral presentation later today at the American Diabetes Association’s (ADA) 78th Scientific Sessions. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza.
WESTLAKE VILLAGE, Calif., June 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) were released today at the American Diabetes Association’s 78th Scientific Sessions, being held June 22-26, 2018, in Orlando, Florida. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza.
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes. MannKind’ s Chief Medical Officer Presenting New Afrezza ® Data Released at American Diabetes Association’ ...
MannKind Corporation (MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administration.
WESTLAKE VILLAGE, Calif., June 05, 2018-- MannKind Corporation has established a stock purchase plan that provides MannKind’ s directors and executive officers with a way to purchase shares of common stock ...
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
On a per-share basis, the Westlake Village, California-based company said it had a loss of 25 cents. Losses, adjusted to extinguish debt, were 24 cents per share. The biopharmaceutical company posted revenue ...
Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 Q1 2018 Net Cash Used in Operating Activities was $21.7 million STAT study results accepted for presentation at American Diabetes Association’ ...
“Our partnership agreement with Cipla for Afrezza provides us with a long-term partner with a wealth of knowledge and experience in diabetes. Cipla is a leader across therapies in India with an established sales, marketing and distribution network. With this partnership, Cipla will leverage its strength in inhalation and extend it to diabetes therapy/portfolio,” stated Michael Castagna, Chief Executive Officer of MannKind. “The International Diabetes Federation estimates that 425 million people are currently living with diabetes worldwide, including 73 million in India.
WESTLAKE VILLAGE, Calif., May 02, 2018-- MannKind Corporation will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the ...
In this article, I’m going to take a look at MannKind Corporation’s (NASDAQ:MNKD) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
WESTLAKE VILLAGE, Calif., April 25, 2018-- MannKind Corporation, focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MannKind Corporation (NASDAQ: MNKD ) stock was trading ...
MannKind Corporation (MNKD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock